Bioorganic and Medicinal Chemistry p. 6974 - 6992 (2015)
Update date:2022-08-15
Topics:
Parker, Erica N.
Song, Jiangli
Kishore Kumar
Odutola, Samuel O.
Chavarria, Gustavo E.
Charlton-Sevcik, Amanda K.
Strecker, Tracy E.
Barnes, Ashleigh L.
Sudhan, Dhivya R.
Wittenborn, Thomas R.
Siemann, Dietmar W.
Horsman, Michael R.
Chaplin, David J.
Trawick, Mary Lynn
Pinney, Kevin G.
Upregulation of cathepsin L in a variety of tumors and its ability to promote cancer cell invasion and migration through degradation of the extracellular matrix suggest that cathepsin L is a promising biological target for the development of anti-metastatic agents. Based on encouraging results from studies on benzophenone thiosemicarbazone cathepsin inhibitors, a series of fourteen benzoylbenzophenone thiosemicarbazone analogues were designed, synthesized, and evaluated for their inhibitory activity against cathepsins L and B. Thiosemicarbazone inhibitors 3-benzoylbenzophenone thiosemicarbazone 1, 1,3-bis(4-fluorobenzoyl)benzene thiosemicarbazone 8, and 1,3-bis(2-fluorobenzoyl)-5-bromobenzene thiosemicarbazone 32 displayed the greatest potency against cathepsin L with low IC50 values of 9.9 nM, 14.4 nM, and 8.1 nM, respectively. The benzoylbenzophenone thiosemicarbazone analogues evaluated were selective in their inhibition of cathepsin L compared to cathepsin B. Thiosemicarbazone analogue 32 inhibited invasion through Matrigel of MDA-MB-231 breast cancer cells by 70% at 10 μM. Thiosemicarbazone analogue 8 significantly inhibited the invasive potential of PC-3ML prostate cancer cells by 92% at 5 μM. The most active cathepsin L inhibitors from this benzoylbenzophenone thiosemicarbazone series (1, 8, and 32) displayed low cytotoxicity toward normal primary cells [in this case human umbilical vein endothelial cells (HUVECs)]. In an initial in vivo study, 3-benzoylbenzophenone thiosemicarbazone (1) was well-tolerated in a CDF1 mouse model bearing an implanted C3H mammary carcinoma, and showed efficacy in tumor growth delay. Low cytotoxicity, inhibition of cell invasion, and in vivo tolerability are desirable characteristics for anti-metastatic agents functioning through an inhibition of cathepsin L. Active members of this structurally diverse group of benzoylbenzophenone thiosemicarbazone cathepsin L inhibitors show promise as potential anti-metastatic, pre-clinical drug candidates.
View MoreChangzhou Anyi Biochem Co., Ltd.(expird)
Contact:+86-519-88836158
Address:no,51 caoda
Hangzhou Haiqiang Chemical Co.,Ltd.
Contact:+86-571-86960370
Address:Add: 5/F, Around Town North Road,No. 10, Hangzhou, Zhejiang,China
Contact:+86-20-32051076
Address:1105,Building A, International Business Incubator,Science City
Beijing Apis Biotechnology Co., Ltd.
Contact:86-010-67856775-8551
Address:NO.4PUHUANGYU ROAD,FENTAI DISTRICT, BEIJING, CHINA
Hebei Think-Do Environment Co., Ltd
website:http://www.thinkdo-environment.com
Contact:0311-86510809
Address:No 6, Shilian Middle Street, Circular Chemical Industry Park
Doi:10.1039/P29750001778
(1975)Doi:10.3390/molecules25081761
(2020)Doi:10.1016/S0020-1693(02)01282-3
(2003)Doi:10.1016/j.ica.2015.11.023
(2016)Doi:10.1021/jo01059a054
(1962)Doi:10.1016/S0957-4166(03)00208-8
(2003)